Kindred Biosciences
KIN
KIN was delisted on the 27th of August, 2021.
72 hedge funds and large institutions have $180M invested in Kindred Biosciences in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 10 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
0.52% less ownership
Funds ownership: 67.94% → 67.42% (-0.52%)
4% less funds holding
Funds holding: 75 → 72 (-3)
13% less capital inflows, than outflows
Capital inflows: $13.8M | Capital outflows: $15.8M
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.55M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
+$2.12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.28M |
| 4 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
+$1.04M |
| 5 |
Goldman Sachs
New York
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ariel Investments
Chicago,
Illinois
|
-$6.91M |
| 2 |
Rubric Capital Management (New York)
New York
|
-$2.5M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.36M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.27M |
| 5 |
Millennium Management
New York
|
-$900K |
KIN Hedge Fund Activity: Q3 2019 in Review
72 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences (KIN) for Q3 2019, worth a combined $180M — down 18% from $221M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KIN and 6 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 30 added.
The largest buyer was Ameriprise, adding an estimated $4.55M. The largest seller was Ariel Investments, cutting an estimated $6.91M.
- 72 institutional investors held Kindred Biosciences (KIN) as of Q3 2019, down from 75 in Q2 2019.
- Funds reported $180M of Kindred Biosciences stock for Q3 2019, down 18% quarter-over-quarter.
- 6 funds opened new Kindred Biosciences positions in Q3 2019 and 10 closed out, a net change of -4 holders.
- The largest Kindred Biosciences buyer in Q3 2019 was Ameriprise, an estimated $4.55M added.
- The largest Kindred Biosciences seller in Q3 2019 was Ariel Investments, an estimated $6.91M sold.
Based on aggregated 13F filings for Q3 2019.